MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-19-0438

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2019

A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.

Tuscano Joseph M, Maverakis Emanual, Groshen Susan, Tsao-Wei Denice, Luxardi Guillaume, Merleev Alexander A, Beaven Anne, DiPersio John F, Popplewell Leslie, Chen Robert, Kirschbaum Mark, Schroeder Mark A, Newman Edward M

Клиническое исследование I фазыСтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Based on the potential for ipilimumab (I) to augment T-cell activation, we hypothesize that ipilimumab would augment the efficacy of rituximab (R) in patients with relapsed/refractory (R/R) CD20+non-Hodgkin's lymphoma (NHL). This phase I study aimed to identify a recommended phase 2 dose, document toxicities, and preliminarily assess efficacy and potential predictive biomarkers.

PATIENTS AND

METHODS

Thirty-three patients with R/R CD20+B-cell lymphoma received R at 375 mg/m2weekly for 4 weeks and I at 3 mg/kg on day 1 and every 3 weeks for four doses. Responding patients went on to maintenance with each agent given every 12 weeks. To facilitate correlative analysis, the expansion phase randomized patients to simultaneous R+I versus R with I delayed 2 weeks.

RESULTS

Toxicity was manageable; no dose-limiting toxicity was observed at the doses studied. When considering the entire cohort, efficacy was modest, with an objective response rate (ORR) of 24% and median progression-free survival (PFS) of 2.6 months. However, in follicular lymphoma patients, the ORR was 58% with a median PFS of 5.6 months. The randomized comparison of R with R+I demonstrated that R+I resulted in more effective B-cell depletion (BCD). Both B-cell depletion and the ratio of CD45RA-regulatory T cell (Treg) to Treg were associated with response at all time points.

CONCLUSIONS

The combination of R+I has manageable toxicity and encouraging efficacy in R/R follicular lymphoma. The ratio of CD45RA-Tregs to total Tregs, and peripheral BCD should be studied further as potential predictors of response.

Для цитирования: Tuscano Joseph M, Maverakis Emanual, Groshen Susan, Tsao-Wei Denice, Luxardi Guillaume, Merleev Alexander A, Beaven Anne, DiPersio John F, Popplewell Leslie, Chen Robert, Kirschbaum Mark, Schroeder Mark A, Newman Edward M. A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019. DOI: 10.1158/1078-0432.ccr-19-0438.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.